Sinularin Exerts Anti-cancer Effects by Inducing Oxidative Stress-mediated Ferroptosis, Apoptosis, and Autophagy in

ZhengPing Wu1, MengQiao Su2,3, HanWu Chen2

  • 1School of Aesthetic Medicine, Yichun University, 576 XueFu Road, Yuanzhou District, Yichun, 336000, Jiangxi Province, China.

Abstract

Insights

Sinularin, a natural compound, effectively inhibits prostate cancer cell growth and triggers cell death pathways. Further research is needed to explore its potential as a therapeutic agent for prostate cancer.

Area of Science:

  • Marine natural products chemistry
  • Cancer biology
  • Pharmacology

Background:

  • Prostate cancer is a leading cause of cancer-related death in men.
  • Sinularin, a compound from soft corals, exhibits anticancer properties in various cancer cells.
  • The specific mechanisms of sinularin's action in prostate cancer remain largely uncharacterized.

Purpose of the Study:

  • To investigate the anticancer effects of sinularin on human prostate cancer cell lines.
  • To elucidate the molecular mechanisms underlying sinularin's anti-prostate cancer activity.

Main Methods:

  • Utilized MTT assays, Transwell assays, and wound healing assays to assess cell viability, invasion, and migration.
  • Employed flow cytometry and western blotting to analyze apoptosis, autophagy, ferroptosis, and key protein expression.
  • Examined effects on androgen receptor (AR) signaling, epithelial-mesenchymal transition (EMT), and oxidative stress markers.

Main Results:

  • Sinularin significantly reduced prostate cancer cell viability and colony formation.
  • It suppressed testosterone-induced growth in LNCaP cells by downregulating AR, 5α-reductase, and PSA.
  • Sinularin inhibited cell invasion, migration, and EMT, while inducing apoptosis, autophagy, and ferroptosis through modulation of specific proteins and reactive oxygen species (ROS).

Conclusions:

  • Sinularin demonstrates potent anticancer effects against prostate cancer cells by targeting the AR signaling pathway and inducing multiple cell death modalities.
  • These findings suggest sinularin holds promise as a potential therapeutic candidate for prostate cancer, warranting further clinical investigation.